Greenwich Lifesciences Inc (GLSI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $18.99 (+3.26%), Market cap $0.38B, 52-week low–high $7.85 ~ $33.56.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018
Financial statements, price targets, institutional (13F) holdings and related news for Greenwich Lifesciences Inc are updated in real time on BlackAll Trade.
Greenwich Lifesciences Inc trades at $18.99 (+3.26%). Real-time quotes and charts are available on BlackAll Trade.
Greenwich Lifesciences Inc has a market cap of about $0.38B.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania